Are there risks from long-term high-dose vitamin B6?

How it works

B6 has a long plasma half-life of around a month and tissue clearance takes longer, which is why neuropathy can present after months to years of high-dose intake and recovery is slow after discontinuation. Distal sensory axons appear most vulnerable to the cellular stress; motor function is typically preserved. The threshold for toxicity has been progressively revised downward as case data has accumulated; recent vigilance data shows neuropathy at intakes well below the older 200 mg/day permissive threshold.

Effective dose

NHS Eatwell guidance is sufficient for adequacy; supplementation for general health is not indicated. NIH ODS US still publishes UL of 100 mg/day, derived from older studies of patients on around 200 mg/day for up to 5 years without overt neuropathy, halved for safety margin; this is the most permissive current position internationally and is increasingly out of step with EFSA and TGA. Australia TGA 2022-2023 lowered supplement dose limit from 200 mg to 100 mg with warning labels now required above 10 mg/day.

Forms compared

Combination products: doxylamine 10 mg plus pyridoxine 10 mg (Xonvea in UK, Diclegis in US) is the licensed UK form for nausea and vomiting in pregnancy. Standalone B6 supplements: 10 mg, 25 mg, 50 mg, and 100 mg products are all marketed; the 50 mg and 100 mg standalone products are now of regulatory concern internationally. B-complex products: B6 content varies; check label.

Timing

There is no specific antidote; management is supportive plus B6 cessation. Anyone with new sensory symptoms (tingling, burning, numbness, sensitivity, balance change) while taking any B6-containing supplement should stop the supplement immediately, audit total daily B6 intake across all products, and seek clinical assessment.

Safety profile

Differential: distinguish from B12 deficiency neuropathy (which has additional dorsal-column features), diabetic peripheral neuropathy, alcohol-related neuropathy, chemotherapy-induced neuropathy. Recent SR: International Journal of Gynecology and Obstetrics 2025 (He et al, DOI 10.1002/ijgo.16032) on potential hazards of high-dose B6 in pregnancy. Cumulative intake from multivitamins, B-complex products, energy drinks, and standalone B6 supplements can substantially exceed the new UL without the user realising.

Special populations

ACOG monotherapy regimen for NVP is 10-25 mg pyridoxine three or four times daily (30-100 mg/day) but this is at the dose range now associated with neuropathy in the Dalton data, so the combination regimen with lower pyridoxine component is preferable. Higher unsupervised doses (above 40 mg/day pyridoxine) should be discouraged in pregnancy. Older adults: standard adult limits apply; sensory neuropathy may be confused with diabetic or age-related neuropathy. Athletes and energy drink users: stack with multivitamins easily exceeds new EFSA UL.

Interactions

Isoniazid (TB therapy): induces B6 deficiency; pyridoxine supplementation 10 mg/day is co-prescribed prophylactically per UK BNF. Hydralazine and penicillamine: also bind pyridoxine; supplementation may be indicated in long-term use. The B6-associated neuropathy is dose-related and not typically problematic at the prophylactic doses used alongside these medications.

Guideline positions

Schaumburg 1983 NEJM 309(8):445-448 (PMID 6308447): seven users on 2-6 g/day for PMS or megavitamin regimen; all developed sensory neuropathy; four unable to walk on presentation. Dalton and Dalton 1987 (Acta Neurologica Scandinavica 76(1):8-11): case-control study at PMS clinic; basis of the EFSA 2023 reference point of 50 mg/day with uncertainty factor of 4. TGA Australia 2022-2023 vigilance data: 32 reports of peripheral neuropathy, two-thirds at intakes below 50 mg/day, no minimum dose, duration, or specific user risk factors identified. Vrolijk 2017 Toxicol In Vitro: mechanistic review of paradoxical B6 deficiency at high pyridoxine intake. UK NICE NG201 (Antenatal care) and RCOG Green-top Guideline 69 (2024) for NVP guidance.

Practical framework

Anyone with new sensory symptoms (tingling, burning, numbness, sensitivity, balance change) on B6 supplementation should stop and seek clinical assessment; do not assume the symptom is unrelated. NHS Eatwell guidance is sufficient for adequacy; supplementation for general health is not indicated. Pregnancy: doxylamine plus pyridoxine combination (Xonvea) is the appropriate licensed UK form for nausea and vomiting; higher unsupervised doses above 40 mg/day pyridoxine should be discouraged. This is a summary of published research, not personal health advice. Discuss any health or supplement decisions with a qualified healthcare professional, particularly during ongoing care, pregnancy, or with chronic conditions.

Common misconceptions

Claim: water-soluble vitamins cannot be toxic. B6 is the canonical exception: pyridoxine at high doses produces a sensory-predominant peripheral neuropathy via paradoxical functional B6 deficiency at the cellular level.

Claim: P5P (pyridoxal-5-phosphate) is safer than pyridoxine HCl at the same dose. The neuropathy phenotype is reported with both forms; EFSA reference applies to total B6 intake regardless of form.

Claim: a single supplement is the only B6 source. Cumulative intake from multivitamins, B-complex, energy drinks, and standalone B6 supplements can exceed the new UL without the user realising.